Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis

Bosch, 2016, Searching for a cure for cystic fibrosis. A 25-year quest in a nutshell, Eur J Pediatr, 175, 1, 10.1007/s00431-015-2664-8 O'Sullivan, 2009, Cystic fibrosis, Lancet, 373, 1891, 10.1016/S0140-6736(09)60327-5 2014 Cai, 2011, Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis, Acta Pharmacol Sin, 32, 693, 10.1038/aps.2011.71 Van Goor, 2011, Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809, Proc Natl Acad Sci USA, 108, 18843, 10.1073/pnas.1105787108 Van Goor, 2009, Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770, Proc Natl Acad Sci USA, 106, 18825, 10.1073/pnas.0904709106 Flume, 2012, Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation, Chest, 142, 718, 10.1378/chest.11-2672 Clancy, 2012, Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation, Thorax, 67, 12, 10.1136/thoraxjnl-2011-200393 Boyle, 2014, A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial, Lancet Respir Med, 2, 527, 10.1016/S2213-2600(14)70132-8 Wainwright, 2015, Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR, N Engl J Med, 373, 220, 10.1056/NEJMoa1409547 Goss, 2007, Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis, Thorax, 62, 360, 10.1136/thx.2006.060889 Steinkamp, 2002, Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project, Thorax, 57, 596, 10.1136/thorax.57.7.596 Quittner, 2009, Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection, Chest, 135, 1610, 10.1378/chest.08-1190